For many healthtech enterprises founded in Europe, it makes a lot of sense to expand and/or raise later-stage funding in the United States. The U.S. offers the promise of massive commercial opportunities, cooperation partnerships and plentiful venture and growth capital.  However, doing business and raising money in an unfamiliar, highly-competitive environment requires thoughtful advance planning and clinical execution.  In this facilitated deep dive presentation and Q&A to follow, we will discuss best practices for navigating the logistical aspects of launching and operating a European-born high-growth business in America and setting and meeting expectations for U.S. later-stage funding. We will also touch upon trends in the rapidly evolving U.S. exit market.